TESARO (TSRO) Misses Q1 EPS by 18c, Completes Enrollment in Phase 3 NOVA Trial

TESARO (NASDAQ: TSRO) reported Q1 EPS of ($1.30), $0.18 worse than the analyst estimate of ($1.12).

TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today provided an update on its niraparib clinical development program. The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter of 2015. In addition, the QUADRA treatment trial of niraparib has been initiated, and initial data from this trial is anticipated in early 2016.

For earnings history and earnings-related data on TESARO (TSRO) click here.

You May Also Be Interested In

• Aon CEO warns AI data centers carry insurance risks
• Starbucks (SBUX) Tops Q4 EPS by 9c, Misses on Revenue; Offers FY27 EPS Guidance
• CareDx (CDNA) Tops Q3 EPS by 44c ; Offers Guidance